



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** SAHA (Vorinostat)

**Catalog Number:** 12130

**Lot Number:** 0420763-30

**Release Category:** E

**Provided:** 20 mg

**Chemical Name:** N<sup>1</sup>-hydroxy-N<sup>8</sup>-phenyl-octanediamide  
Synonyms: Suberoylanilide Hydroxamic Acid, Vorinostat, Zolina™

**Empirical Formula:** C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>

**HPLC Purity:** >98%

**Molecular Weight:** 264.3

**CAS Num:** 149647-78-9

**Solubility:** SAHA is soluble in organic solvents such as ethanol (250 µg/mL); and in DMSO, and dimethyl formamide (DMF), at approximately 20 mg/mL. For maximum solubility in aqueous buffers, SAHA should first be dissolved in DMSO and then diluted in aqueous buffer of choice. SAHA has an approximate solubility of 0.5 mg/mL in a 1:1 solution of DMSO:PBS (7.2). **Storage in aqueous buffer is not recommended for longer than one day.**

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Mechanical  
Action:**

SAHA is a histone deacetylase (HDAC) inhibitor that binds directly to the catalytic site of the enzyme thereby blocking substrate access. It inhibits class I and II HDACs at around 50 nM and arrests cell growth in a wide variety of transformed cells in culture at 2.5-5.0  $\mu$ M (1). SAHA is currently in advanced clinical trials for the treatment of cancer.

**WARNING:** The toxicological properties of this product have not been fully evaluated. This material may be irritating to the mucous membranes and upper respiratory tract. May be harmful by inhalation, ingestion, or skin absorption. May cause eye, skin, or respiratory system irritation.

[MSDS: SAHA \(Vorinostat\)](#)

**Recommended  
Storage:**

-20°C

**Contributor:**

NIAID, DAIDS

**References:**

Marks, P. A., & Breslow, R. (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. *Nat Biotechnol*, 25(1), 84-90. doi:10.1038/nbt1272 [PUBMED](#)

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: SAHA (Vorinostat) from NIAID, DAIDS (cat# 12130)."

**This compound is for laboratory research use ONLY. This compound is NOT intended for human or veterinary diagnostic or therapeutic use.**

**Last Updated**

January 17, 2019

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.